On November 20, 2018 Genmab A/S (Nasdaq Copenhagen: GEN) reported that data from the Phase III MAIA study of daratumumab in front line multiple myeloma, which was submitted by our collaboration partner Janssen Biotech, Inc., was accepted as a late-breaking abstract for oral presentation at the 60th Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper) (Press release, Genmab, NOV 20, 2018, View Source [SID1234531503]). The abstract is now published online on the ASH (Free ASH Whitepaper) website:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
LBA-2: Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA) (View Source)
The data will be presented as part of the Late-Breaking Abstracts Session on December 4, 2018 at 7:30 AM PST (4:30 PM CET).
"We are extremely pleased that this new data from the important MAIA study has been chosen for presentation at the prestigious ASH (Free ASH Whitepaper) annual meeting, as it will provide ASH (Free ASH Whitepaper) attendees the opportunity to learn more about the transformative role of daratumumab in the treatment of newly diagnosed patients with multiple myeloma," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab